TSRO - Tesaro, Inc.
| Previous Close | 48.58 |
| Open | 48.50 |
| Bid | 51.50 x 1800 |
| Ask | 51.75 x 1400 |
| Day's Range | 48.25 - 51.79 |
| 52 Week Range | 44.76 - 168.92 |
| Volume | 1,268,605 |
| Avg. Volume | 1,181,728 |
| Market Cap | 2.838B |
| Beta | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool•4 days ago
Is This Stock the Next Biotech Acquisition Target?
Optimism is growing that this cancer drug developer will be the next biotech to be acquired.
- Market Realist•4 days ago
Analyzing Tesaro’s Financial Performance
Tesaro (TSRO) generated total revenues of $49.7 million in the first quarter—compared to $3 million in the first quarter of 2017. Tesaro’s licensing and collaboration revenues were $934,000 in the first quarter of 2017. The change was due to a $1 million reversal of milestone payments recognized by Tesaro in 2015 and 2016 from the Hengrui license agreement. Tesaro concluded that the agreement probably wouldn’t be achieved.
Market Realist•4 days agoHow Are Tesaro’s Valuations and Cash Flows?
Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.
Market Realist•4 days agoTesaro’s Zejula Promises Significant Growth
Tesaro’s (TSRO) products on the market are Zejula and Varubi. Zejula has been approved in the United States and the European Union as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Varubi has been approved in the United States and the European Union in combination with other antiemetic agents in adults to prevent delayed nausea and vomiting associated with chemotherapy.
Market Realist•4 days agoTesaro Stock: What’s the Upside Potential?
Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.
- Simply Wall St.•5 days ago
How Confident Are Insiders About Tesaro Inc (NASDAQ:TSRO)?
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. Tesaro’s insiders have invested 150,532 shares in theRead More...
- Market Realist•13 days ago
How Lynparza Performed in 1Q18
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza. In 1Q18, Merck reported $33 million as its share of the Lynparza alliance revenues, of which $24 million were earned in US markets, while the remaining $9.0 million were reported from international markets. Lynparza is currently the leading PARP inhibitor in terms of new and total prescriptions for its approved label in ovarian cancer and breast cancer indications.
- Bloomberg•16 days ago
Former Biotech Darlings Tesaro, Clovis Pin Hopes on 2018 Rebound
Considered a year ago to be among the top takeover targets in biotech, Tesaro Inc. and Clovis Oncology Inc. have so far failed to live up to their hype on Wall Street. Shares of Tesaro have fallen 71 percent since the U.S. Food and Drug Administration approved its ovarian cancer drug Zejula in March 2017. Clovis is down 32 percent over that time as its competing therapy has also struggled to meet sales estimates.
- Simply Wall St.•17 days ago
With A -24.35% Earnings Drop, Is Tesaro Inc’s (NASDAQ:TSRO) A Concern?
When Tesaro Inc (NASDAQ:TSRO) released its most recent earnings update (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of TSRO earnings conference call or presentation 3-May-18 8:15pm GMT
Q1 2018 TESARO Inc Earnings Call
- Benzinga•23 days ago
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
- Investor's Business Daily•23 days ago
Tesaro Dives After First-Quarter Sales Lag On Wider-Than-Expected Losses
Tesaro on Thursday reported a loss of $2.98 per share on $49.7 million in revenue for its first quarter.
- Associated Press•23 days ago
Tesaro: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $2.98. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
- Investor's Business Daily•last month
Can This Smaller Biotech Actually Rival Merck, Bristol In Cancer Drugs?
Tesaro popped Monday after unveiling early data for a potential competitor to drugs from Dow Jones component Merck and Bristol.
- Investopedia•last month
3 Biotech Stocks Analysts Have Been Too Bullish On
Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last month, ETFs holding TSRO are favorable, with net inflows of $5.12 billion.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TSRO presentation 6-Mar-17 1:40pm GMT
TESARO Inc at Raymond James Institutional Investors Conference
- Motley Fool•2 months ago
Tesaro Wants a Stronger Grip in Ovarian Cancer
Management revealed data this week that could help the company against its competitors.
- Investor's Business Daily•2 months ago
Tesaro Sinks After Unveiling Results Of Merck-Tied Ovarian Cancer Study
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Eclipse Resources Corp (NYSE: ECR ) stock was trading ...
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
- Motley Fool•3 months ago
AstraZeneca Goes Up Against 2 Cancer Upstarts
Tesaro and Clovis Oncology hope to unseat the big pharma giant, but they've got their work cut out for them.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of TSRO earnings conference call or presentation 27-Feb-18 9:15pm GMT
Q4 2017 TESARO Inc Earnings Call
- GuruFocus.com•3 months ago
Tesaro Inc (TSRO) CEO Leon O Jr Moulder Bought $284,650 of Shares
CEO of Tesaro Inc (NASDAQ:TSRO) Leon O Jr Moulder bought 5,000 shares of TSRO on 03/02/2018 at an average price of $56.93 a share.
- Market Realist•3 months ago
AstraZeneca’s Lynparza Witnessed High Growth in 2017
An In-Depth Look into AstraZeneca's 4Q17 Performance
